123 See

Website

123 See, Inc.

8 Investors
Health Technology & Medical Devices
BOSTON, MA

123 See, Inc., operating as Eyebot, is a vision technology startup dedicated to making vision care more accessible and affordable. The company develops and deploys self-serve vision testing kiosks in high-traffic retail locations, addressing the gap between the demand for vision care and the availability of traditional eye doctors.

Products & Team

Eyebot Vision Testing Kiosk

Vision Testing KioskSeed

The Eyebot Vision Testing Kiosk is a self-serve station designed for retail environments that conducts rapid vision tests. After a free initial screening, users can pay a fee to have their results reviewed remotely by a licensed eye doctor, who then issues a valid prescription delivered via email and integrated with the retailer's system.

Value Proposition

The kiosk solves the problem of limited access to convenient and affordable vision exams by providing an on-demand, low-cost alternative to traditional optometrist appointments, eliminating barriers related to cost, time, and scheduling.

Pain Points

The service addresses common customer frustrations such as the high cost of traditional eye exams, the time commitment required for appointments, and the difficulty in scheduling with eye care professionals.

Proprietary gaze-independent, contactless autorefractor technology that enhances accuracy.Rapid testing process completed in approximately 90 seconds.Comprehensive screening capabilities for refractive error, lensometry, visual acuity, and indications of conditions like cataracts.An AI-powered system for initial analysis, followed by a remote review by a licensed doctor for prescription issuance.An intuitive, easy-to-use interface designed for a broad range of consumers.
Industry
Other Technology
Primary business sector
Founded
2025
Year established
Location
BOSTON, MA
Primary headquarters

Funding History

Total Raised:
$22.0M
E

Equity Offering

July 2025
$22.1M
Target
Use of Proceeds
Secondary Sale
Progress
99%
Raised
$22.0M
Target
$22.1M
#000202238225000002